FDA MAY SOON ALLOW MDMA PRESCRIPTIONS FOR PTSD.

AuthorSullum, Jacob
PositionDRUGS - Post-traumatic stress disorder

"I WAS FINALLY able to process all the dark stuff that happened," Nicholas Blackston, a Marine veteran who served in Iraq, told The New York Times, describing his experience with MDMA-assisted psychotherapy. "I was able to forgive myself. It was like a clean sweep."

MDMA, which was banned by the Drug Enforcement Administration in 1985, could be available by prescription as soon as 2021. The rehabilitation of MDMA, a.k.a. "ecstasy" or "molly," is directly related to the rehabilitation of veterans like Blackston, who participated in a study that confirmed the drug's potential as a catalyst for catharsis.

The trial was sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and reported on May 1 in The Lancet Psychiatry. It involved 22 military veterans, three firefighters, and one police officer, all of whom had been diagnosed with chronic post-traumatic stress disorder (PTSD) "resulting from traumatic experience during their service." The researchers, led by Charleston, South Carolina, psychiatrist Michael Mithoefer, randomly assigned the participants to receive 30, 75, or 125 milligrams of MDMA in conjunction with two psychotherapy sessions separated by about a month. The lowest dose served as an "active placebo." Neither the researchers nor the subjects knew who was receiving which amount.

The results were striking. Average scores on the Clinician Administered PTSD Scale (CAPS), which indicates symptom severity, fell by 71 percent in the medium-dose group and 49 percent in the high-dose group...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT